Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $263,560.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $131.78, for a total value of $263,560.00. Following the completion of the sale, the director owned 412,326 shares of the company’s stock, valued at approximately $54,336,320.28. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $139.48 on Monday. The stock’s fifty day moving average price is $123.75 and its two-hundred day moving average price is $115.49. The firm has a market cap of $8.46 billion, a PE ratio of -20.73, a price-to-earnings-growth ratio of 8.65 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the business posted $5.30 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on JAZZ shares. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Finally, The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in JAZZ. Teacher Retirement System of Texas increased its stake in shares of Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after purchasing an additional 90 shares during the last quarter. Kendall Capital Management boosted its position in shares of Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock valued at $989,000 after acquiring an additional 95 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in Jazz Pharmaceuticals by 0.6% in the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock valued at $2,098,000 after acquiring an additional 100 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its stake in shares of Jazz Pharmaceuticals by 8.7% during the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock worth $133,000 after acquiring an additional 100 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 1.3% in the first quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company’s stock worth $1,046,000 after buying an additional 110 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.